IP Library Patent Application 12162572
Patent Application
App. No. 12/162,572

SUTURES AND ANTI-SCARRING AGENTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/162,572
Abstract

Sutures are used in combination with anti-scarring agents to inhibit fibrosis between the sutures and the host tissues into which the sutures are inserted. Compositions and methods are described for use in reducing excessive scarring, surgical adhesion, and other disorders.

Claims (20)

1 .- 35 . (canceled)

36 . An anti-scarring suture, comprising: a self-retaining suture and an anti-scarring agent.

37 . The anti-scarring suture of claim 36 , wherein the anti-scarring agent is an anti-microbial agent, an anti-angiogenic agent, an anti-inflammatory agent, a heat shock protein 90 (HSP90) antagonist, a histamine receptor antagonist, an anesthetic, a protein, a peptide, an anti-thrombotic agent, an anti-platelet agent, or a steroid.

38 . The anti-scarring suture of claim 37 , wherein the anti-microbial agent is an anti-mycotic agent.

39 . The anti-scarring suture of claim 38 , wherein the anti-mycotic agent is terbinafine, staurosporine, itraconazole, or miconazole.

40 . The anti-scarring suture of claim 37 , wherein the anti-microbial agent is an anthracycline, fluoropyrimidine, folic acid antagonist, or podophylotoxin.

41 . The anti-scarring suture of claim 37 , wherein the anti-angiogenic agent is paclitaxel.

42 . The anti-scarring suture of claim 37 , wherein the HSP90 antagonist is geldanamycin.

43 . The anti-scarring suture of claim 37 , wherein the histamine receptor antagonist is famotidine.

44 . The anti-scarring suture of claim 36 , further comprising a polymer.

45 . The anti-scarring suture of claim 44 , wherein the polymer is a polymeric carrier of the anti-scarring agent.

46 . A method for making the anti-scarring suture of claim 36 , comprising: combining a self-retaining suture with an anti-scarring agent or a composition comprising an anti-scarring agent.

47 . A method for reducing, or reducing the risk of, excessive scarring, comprising implanting the anti-scarring suture of claim 36 into a tissue.

48 . The method of claim 47 , wherein the excessive scarring is at a wound closure site, a site of attachment of a foreign element to a tissue, or a site of a tissue repositioning surgery.

49 . The method of claim 47 , wherein the excessive scarring results in a keloid or hypertrophic scar.

50 . The method of claim 47 , wherein the excessive scarring results in surgical adhesion.

51 . A method for reducing, or reducing the risk of, excessive scarring, comprising infiltrating a tissue at which a self-retaining suture has been, is being, or to be, implanted with an effective amount of an anti-scarring agent or a composition comprising an anti-scarring agent.

52 . The method of claim 51 , wherein the excessive scarring is at a wound closure site, a site of attachment of a foreign element to a tissue, or a site of a tissue repositioning surgery.

53 . The method of claim 51 , wherein the excessive scarring results in a keloid or hypertrophic scar.

54 . The method of claim 51 , wherein the excessive scarring results in surgical adhesion.

Assignments (6)
RELEASE OF SECURITY INTEREST : RECORDED AT REEL/FRAME - 049288/0184 Recorded Jan 29, 2021
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: ANGIOTECH PHARMACEUTICALS, INC.
Reel/Frame 055171/0634 →
SECURITY INTEREST Recorded May 26, 2019
From: ANGIOTECH PHARMACEUTICALS, INC.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 049288/0184 →
RELEASE OF SECURITY INTEREST Recorded Sep 4, 2013
From: WELLS FARGO FOOTHILL, LLC
To: ANGIOTECH PHARMACEUTICALS, INC.; ANGIOTECH AMERICA, INC.; SURGICAL SPECIALTIES CORPORATION (US), INC., FORMERLY KNOWN AS ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; ANGIOTECH INTERNATIONAL HOLDINGS CORP.
Reel/Frame 031157/0186 →
RELEASE OF SECURITY INTEREST Recorded Apr 15, 2013
From: DEUTSCHE BANK NATIONAL TRUST COMPANY
To: ANGIOTECH PHARMACEUTICALS, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; ANGIOTECH INTERNATIONAL HOLDINGS CORP.
Reel/Frame 030218/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2009
From: AVELAR, RUI; MAITI, ARPITA; TOLEIKIS, PHILIP M.; CASHMAN, JOHANNE DIANE; GRAVETT, DAVID M.
To: ANGIOTECH PHARMACEUTICALS, INC.
Reel/Frame 022648/0834 →
SECURITY AGREEMENT Recorded Mar 2, 2009
From: ANGIOTECH PHARMACEUTICALS, INC.; AFMEDICA, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH CAPITAL, LLC; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; CRIMSON CARDINAL CAPITAL, LLC; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; NEUCOLL INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; 0741693 BRITISH COLUMBIA LTD.; 3091796 NOVA SCOTIA COMPANY; ANGIOTECH INTERNATIONAL HOLDINGS, CORP.; ANGIOTECH INVESTMENT PARTNERSHIP
To: WELLS FARGO FOOTHILL, LLC AS AGENT
Reel/Frame 022329/0310 →